Compositions and methods for modulating metabolic pathways
First Claim
Patent Images
1. A composition comprising:
- (a) leucine and/or one or more leucine metabolites selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and hydroxymethylbutyrate (HMB); and
(b) a sirtuin-pathway activator;
wherein molar ratio of component (a) to (b) in said composition is greater than about 20, and wherein the composition when administered to a subject in need thereof synergistically enhances mitochondrial biogenesis as measured by a decrease in weight gain of a subject, a decrease in visceral adipose volume of a subject, an increase in fat oxidation of a subject, an increase in irisin production of a subject, an increase in insulin sensitivity of a subject, an increase of glucose uptake in muscle of a subject, a decrease in inflammation markers, an increase in vasodilatation, and/or an increase in body temperature;
wherein the composition is substantially free of non-branched amino acids; and
wherein the composition comprises at least about 500 mg of leucine and/or at least about 200 mg of the one or more leucine metabolites.
2 Assignments
0 Petitions
Accused Products
Abstract
Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.
73 Citations
22 Claims
-
1. A composition comprising:
-
(a) leucine and/or one or more leucine metabolites selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and hydroxymethylbutyrate (HMB); and (b) a sirtuin-pathway activator; wherein molar ratio of component (a) to (b) in said composition is greater than about 20, and wherein the composition when administered to a subject in need thereof synergistically enhances mitochondrial biogenesis as measured by a decrease in weight gain of a subject, a decrease in visceral adipose volume of a subject, an increase in fat oxidation of a subject, an increase in irisin production of a subject, an increase in insulin sensitivity of a subject, an increase of glucose uptake in muscle of a subject, a decrease in inflammation markers, an increase in vasodilatation, and/or an increase in body temperature; wherein the composition is substantially free of non-branched amino acids; and wherein the composition comprises at least about 500 mg of leucine and/or at least about 200 mg of the one or more leucine metabolites. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A food composition comprising:
-
(a) leucine and/or one or more leucine metabolites selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and hydroxymethylbutyrate (HMB); (b) a sirtuin pathway activator, wherein (a) and (b) are present in an amount that synergistically effect an increase in sirtuin pathway output as measured by a decrease in weight gain of a subject, a decrease in visceral adipose volume of a subject, an increase in fat oxidation of a subject, an increase in insulin sensitivity of a subject, an increase of glucose uptake in muscle of a subject, an increase in vasodilatation, and/or an increase in body temperature; and (c) a food carrier; wherein molar ratio of component (a) to (b) in said composition is greater than about 20; wherein the composition is substantially free of non-branched amino acids; and wherein the composition comprises at least about 500 mg of leucine and/or at least about 200 mg of the one or more leucine metabolites. - View Dependent Claims (11, 12, 13, 14, 15, 16)
-
-
17. A composition comprising a unit dosage suitable for oral ingestion, said unit dosage comprising:
-
(a) leucine and/or one or more leucine metabolites selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and hydroxymetylbutyrate (HMB); and (b) a substantially homogeneous population of polyphenol or polyphenol precursor molecules; wherein the unit dosage is effective in inducing an increase in sirtuin pathway output as measured by a decrease in weight gain of a subject, a decrease in visceral adipose volume of a subject, an increase in fat oxidation of a subject, an increase in insulin sensitivity of a subject, an increase of glucose uptake in muscle of a subject, an increase in vasodilatation, and/or an increase in body temperature; wherein molar ratio of component (a) to (b) in said composition is greater than about 20; wherein the composition is substantially free of non-branched amino acids; and wherein the composition comprises at least about 500 mg of leucine and/or at least about 200 mg of the one or more leucine metabolites. - View Dependent Claims (18, 19, 20, 21, 22)
-
Specification